Palantir Slides, Hims Rises, Constellation Jumps on Nuclear Deal Plans
May 6, 2025
Palantir's stock took a sharp dive after disappointing earnings, even as it forecasts rising AI demand. Meanwhile, Hims & Hers's shares climbed thanks to unexpectedly strong sales, raising intrigue about its shift to selling discounted weight-loss medications. Constellation Energy's stock saw a boost as it nears long-term nuclear energy contracts, reflecting a solid response to growing energy demands. The interplay of AI stocks and the energy sector generates fascinating market drama.
06:07
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
Palantir's Growth and Valuation Challenges
Palantir's shares slid despite beating earnings and raising revenue forecast because investors questioned its valuation and international growth.
Its commercial growth beats were concentrated in the U.S., while international business showed limited traction.
insights INSIGHT
Palantir and AI Momentum Trade
Palantir symbolizes the AI momentum trade with high retail interest, leading to rapid stock gains.
After a strong April, traders await May to see if the momentum will sustain or weaken.
insights INSIGHT
Nuclear Energy Boosts Constellation Stock
Constellation Energy stock rose on news of nearing long-term nuclear power deals despite earnings miss.
Investors react positively to nuclear energy as a growing theme tied to rising power demand for AI and electrification.
Get the Snipd Podcast app to discover more snips from this episode
- Palantir Technologies (PLTR) shares slid by the most in nearly a year after its financial results and projections failed to live up to investors’ lofty expectations. The company described rising demand for artificial intelligence software as a “ravenous whirlwind” and bumped its 2025 revenue forecast on Monday to about $3.9 billion from about $3.75 billion. But even a solid earnings results beat and the raised outlook wasn’t enough to justify the stock’s high valuation and extend its massive year-to-date gain. Palantir’s shares tanked by as much as 14.9% to $105.32, the lowest intraday price since May 7, 2024. The stock was still up 41% for the year.
- Hims & Hers Health Inc. (HIMS) reiterated its 2025 revenue forecast after posting better-than-expected sales for the first quarter, raising questions about the future as it shifts from making copycat weight-loss drugs to selling discounted versions of Novo Nordisk A/S’s blockbuster Wegovy. Hims’ business got a boost when branded weight-loss drugs were in short supply and a regulatory loophole allowed it to sell less expensive compounded versions of drugs like semaglutide, a chemical name for Wegovy. Those shortages have since resolved and now the telehealth company is finding a new lane by also selling branded drugs at a discount.
- Constellation Energy (CEG) surged after it said it is on the verge of signing long-term deals to provide nuclear energy that could meet unrelenting demand to run data centers and factories. Shares climbed 12% as Chief Executive Officer Joe Dominguez said on an earnings call that the agreements bolster the case for Constellation’s pending $16.4 billion deal for Calpine, which would give Constellation the largest fleet of US power stations. Power consumption in the US is expected to grow almost 16% over the next five years, driven by data centers running artificial intelligence operations, as well as the electrification of homes and cars and a shift away from fossil fuels in manufacturing. That’s created new life for old nuclear plants, with a deal to reopen Three Mile Island as the most high-profile example.
Stock Movers